Lurbinectedin + Doxorubicin In Leiomyosarcoma
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Active, not recruiting · NCT05099666 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lurbinectedin + Doxorubicin In Leiomyosarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT05099666 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jazz Pharmaceuticals | 60 |
| Massachusetts General Hospital | 758 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Massachusetts General Hospital | Boston | United States | 39 |
| Mayo Arizona | Phoenix | United States | 2 |
| Mayo Jacksonville | Jacksonville | United States | 4 |
| Mayo Rochester | Rochester | United States | 5 |
| Memorial Sloan Kettering | New York | United States | 27 |